Clinical Trial Update: Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of elsamitrucin (SPI 28090) for relapsed/refractory non-Hodgkin's lymphoma has completed enrollment/status. The update does not report trial outco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Elsamitrucin

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED